June 2021

home / publications / evidence-based-oncology / june-2021

Dollars and Sense

Joseph Alvarnas, MD

June 23rd 2021

ArticleFROM THE EDITORS

FDA Panel Votes to Keep 4 of 6 “Dangling Approvals,” in a Sign of Things to Come

Mary Caffrey

June 22nd 2021

Article

Observations Regarding the Average Sales Price Reimbursement Methodology

Susan Weidner, MBA, MS;Michael Diaz, MD;Cass Schaedig;Lucio Gordan, MD

June 21st 2021

ArticleCOVER FEATURE

Weidner et al, Appendices

Susan Weidner, MBA, MS;Michael Diaz, MD;Cass Schaedig;Lucio Gordan, MD

June 21st 2021

ArticleCOVER FEATURE

Appendices to: Observations Regarding the Average Sales Price Reimbursement Methodology

Real-World Evidence Is Key to Accelerating Oncology Approvals

Jennifer B. Christian, PharmD, MPH, PhD

June 21st 2021

ArticleCOMMENTARY

PATHWAYS: Oncology Care Pathways Launched by Payers: What Are the Trends?

Allison Inserro

June 20th 2021

Article

Keely Macmillan, MSPH

June 19th 2021

ArticleCOVER FEATURE

A Social Worker Leads ACCC, and Her Timing Is Perfect

Mary Caffrey

June 19th 2021

ArticleCOVER FEATURE

After PD-1 Inhibitor Indications Are Withdrawn in SCLC, What Now?

Mary Caffrey

May 26th 2021

Article

Martin J. Edelman, MD, chair of the Department of Hematology/Oncology and associate director for Translational Research at the Fox Chase Cancer Center in Philadelphia, Pennsylvania, discusses the the nuances of rescinded indications in small-cell lung cancer.

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777